Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
Sponsor: Teva Branded Pharmaceutical Products R&D LLC
Summary
The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.
Official title: An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
Key Details
Gender
All
Age Range
30 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-09-30
Completion Date
2029-05-17
Last Updated
2026-04-09
Healthy Volunteers
No
Conditions
Interventions
TEV-56286
administered orally
Locations (11)
Teva Investigational Site 15544
Boca Raton, Florida, United States
Teva Investigational Site 15555
Tampa, Florida, United States
Teva Investigational Site 15543
Spokane, Washington, United States
Teva Investigational Site 35290
Bordeaux, France
Teva Investigational Site 32818
Dresden, Germany
Teva Investigational Site 80203
Haifa, Israel
Teva Investigational Site 30299
Bologna, Italy
Teva Investigational Site 84141
Sanda-shi, Japan
Teva Investigational Site 31324
Barcelona, Spain
Teva Investigational Site 31323
Barcelona, Spain
Teva Investigational Site 31322
Seville, Spain